{"title":"Study of Plasma Corticosterone Upon Chronic Stress Induction and Its Effect on Follicular Development in Rattus norvegicus","authors":"Nitin Kalsi Rajashekara, Bindu Jayashankaraswamy, Raghuram Nataraj.","doi":"10.14740/jem880","DOIUrl":"https://doi.org/10.14740/jem880","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":"1 1","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67230176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Assessment and Therapy of Five Hundred Five Patients With Primary Hyperparathyroidism","authors":"J. Tucci","doi":"10.14740/jem847","DOIUrl":"https://doi.org/10.14740/jem847","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48054064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdulhameed Alhazmi, Wael M. Almistehi, Moeber M. Mahzari
Telemedicine (TM) can be defined as the practice of medicine using technology such as video teleconferencing, telephone calls, or emails in order to provide health care from a distance. The emergence of the coronavirus disease 2019 (COVID-19) pandemic and its potential complications have created an urgent need for the transformation of physical visits into virtual encounters. Pituitary adenomas are one of the common endocrine tumors and can manifest with hormonal or mass effects. COVID-19 impacted the common pathway of diagnosis and treatment of these masses. TM utilization for pituitary adenomas has not been addressed thoroughly in the literature despite how common they are. In this review article, we discuss and implement what has been written in the literature about TM for pituitary adenoma alongside our suggested protocol.
{"title":"Approach to the Patient With Pituitary Adenoma Using Telemedicine: Knowledge Gaps and Recommendations","authors":"Abdulhameed Alhazmi, Wael M. Almistehi, Moeber M. Mahzari","doi":"10.14740/jem866","DOIUrl":"https://doi.org/10.14740/jem866","url":null,"abstract":"Telemedicine (TM) can be defined as the practice of medicine using technology such as video teleconferencing, telephone calls, or emails in order to provide health care from a distance. The emergence of the coronavirus disease 2019 (COVID-19) pandemic and its potential complications have created an urgent need for the transformation of physical visits into virtual encounters. Pituitary adenomas are one of the common endocrine tumors and can manifest with hormonal or mass effects. COVID-19 impacted the common pathway of diagnosis and treatment of these masses. TM utilization for pituitary adenomas has not been addressed thoroughly in the literature despite how common they are. In this review article, we discuss and implement what has been written in the literature about TM for pituitary adenoma alongside our suggested protocol.","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46629154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Application of Self-Monitoring of Blood Glucose by Intermittently Scanned Continuous Glucose Monitoring to Lifestyle Improvement After Health Checkup","authors":"T. Kakuma, Takashi Tsutsumi, Yoshikuni Kudo","doi":"10.14740/jem875","DOIUrl":"https://doi.org/10.14740/jem875","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44379809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intensive Management of Poorly Controlled Type 2 Diabetes Using a Multidisciplinary Approach and Continuous Glucose Monitoring","authors":"Andrew J. Behnke, D. Woodfield","doi":"10.14740/jem844","DOIUrl":"https://doi.org/10.14740/jem844","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45221192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serum Apelin Level in Type 2 Diabetic Mellitus Patients and Its Association With Metabolic Syndrome Components","authors":"Hayder Abdulameer Hammood Saadi, Mahdieh Safarzad, Nahid Poursharifi, Mahin Tatari, A. Marjani","doi":"10.14740/jem876","DOIUrl":"https://doi.org/10.14740/jem876","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45910113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: I-131 (radioactive iodine (RAI)) therapy effectively targets overactivity of the thyroid gland; however, the literature provides conflicting outcomes regarding dosage optimization of I-131 for patients with hyperthyroidism and associated clinical complications. This retrospective study aimed to validate the therapeutic efficacy of an empirically derived I-131 institution formula in resolving hyperthyroidism by establishing a euthyroid or hypothyroid state. Methods: This retrospective chart review was undertaken for 89 adult patients (> 18 years) who received I-131 therapy from 2016 to 2020 at H&H/Queens, New York. The I-131 dose range was determined in accordance with their thyroid gland weight and thyroid uptake percentages; however, the follow-up assessment was performed for a duration of 6 - 12 months. IRB approval with reference HS-STUDY-21-01760 was obtained. All the subjects consented using a written consent document in a private room. All the patient’s data are stored confidentially in a password-protected computer, which is accessible only to the study group. The primary endpoint (i.e., treatment success) was defined by the interim development of a euthyroid state, hypothyroidism, subclinical/questionable/suspected hypothyroidism, or a questionable euthyroid state. The secondary endpoints included the frequency of repeat RAI doses and post-ablation thyroid function tests (TFTs). Results: The univariate and multivariate analysis of patient data indicated an 83% I-131 treatment success rate defined by the achievement of a euthyroid state and hypothyroidism in 6.7% and 70.8% of patients, along with the attainment of questionable euthyroid status, questionable hypothyroidism, subclinical hypothyroidism, and suspected hypothyroidism in 1.1%, 1.1%, 2.2%, and 1.1% of patients, respectively. In addition, a low number (i.e., 9%) of patients with hyperthyroidism required repeat I-131 treatment dosages to achieve a hypothyroid or euthyroid state. The results indicated a clinically significant impact of I-131 treatment dosages on post-ablation thyroid-stimulating hormone (TSH), triiodothyronine (T3), and free thyroxin (FT4) levels. Conclusion: The results of this study testified to the therapeutic efficacy of the current institution’s formula for I-131 treatment dosages in treating hyperthyroidism. In addition, 83% treatment success and a low retreatment requirement strengthened current evidence favoring the optimization of RAI therapy for hyperthyroidism. J Endocrinol Metab. 2023;13(2):49-56 doi: https://doi.org/10.14740/jem874
{"title":"Efficacy of I-131 Treatment Dosage for Hyperthyroidism With Current Institution Formula","authors":"Sanna Salam, Nso Nso, Ravali Kondaveeti, Tsung Han Scottie Ching, Mahmoud Nassar, Issac Sachmechi","doi":"10.14740/jem874","DOIUrl":"https://doi.org/10.14740/jem874","url":null,"abstract":"Background: I-131 (radioactive iodine (RAI)) therapy effectively targets overactivity of the thyroid gland; however, the literature provides conflicting outcomes regarding dosage optimization of I-131 for patients with hyperthyroidism and associated clinical complications. This retrospective study aimed to validate the therapeutic efficacy of an empirically derived I-131 institution formula in resolving hyperthyroidism by establishing a euthyroid or hypothyroid state. Methods: This retrospective chart review was undertaken for 89 adult patients (> 18 years) who received I-131 therapy from 2016 to 2020 at H&H/Queens, New York. The I-131 dose range was determined in accordance with their thyroid gland weight and thyroid uptake percentages; however, the follow-up assessment was performed for a duration of 6 - 12 months. IRB approval with reference HS-STUDY-21-01760 was obtained. All the subjects consented using a written consent document in a private room. All the patient’s data are stored confidentially in a password-protected computer, which is accessible only to the study group. The primary endpoint (i.e., treatment success) was defined by the interim development of a euthyroid state, hypothyroidism, subclinical/questionable/suspected hypothyroidism, or a questionable euthyroid state. The secondary endpoints included the frequency of repeat RAI doses and post-ablation thyroid function tests (TFTs). Results: The univariate and multivariate analysis of patient data indicated an 83% I-131 treatment success rate defined by the achievement of a euthyroid state and hypothyroidism in 6.7% and 70.8% of patients, along with the attainment of questionable euthyroid status, questionable hypothyroidism, subclinical hypothyroidism, and suspected hypothyroidism in 1.1%, 1.1%, 2.2%, and 1.1% of patients, respectively. In addition, a low number (i.e., 9%) of patients with hyperthyroidism required repeat I-131 treatment dosages to achieve a hypothyroid or euthyroid state. The results indicated a clinically significant impact of I-131 treatment dosages on post-ablation thyroid-stimulating hormone (TSH), triiodothyronine (T3), and free thyroxin (FT4) levels. Conclusion: The results of this study testified to the therapeutic efficacy of the current institution’s formula for I-131 treatment dosages in treating hyperthyroidism. In addition, 83% treatment success and a low retreatment requirement strengthened current evidence favoring the optimization of RAI therapy for hyperthyroidism. J Endocrinol Metab. 2023;13(2):49-56 doi: https://doi.org/10.14740/jem874","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135220152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: This study aimed to estimate the prevalence of osteoporosis among patients with adrenal Cushing’s syndrome (ACS) and Cushing’s disease (CD), to investigate whether there is a difference in the degree of osteoporosis between both groups; and if so, what factors may be responsible for this variation. Methods: This is a cross-sectional study in which data from 19 patients with CD and eight patients with ACS were analyzed. Osteo-porosis was assessed using the bone mineral density (BMD) of the lumbar spine using dual-energy X-ray absorptiometry (DEXA). Results: Bone loss was present in 81.5% of the patients with Cushing’s syndrome. Osteoporosis is nearly three times more common in ACS (62.5%) than in CD (26.3%). BMD at the lumbar spine was lower in patients with ACS than in patients with CD. ACS had significantly lower levels of dehydroepiandrosterone sulfate (DHEA-S) than CD. In comparison to the CD group, the serum parathyroid hormone (PTH) concentration in the ACS group was significantly higher. In the entire patient population, there was a statistically significant correlation between the DHEA-S and the lumbar BMD values. Conclusions: Patients with ACS have more severe osteoporosis than patients with CD, and the difference in DHEA-S concentrations might be important in explaining this difference. BMD examinations should be prioritized to enable rapid recognition and intervention for osteoporosis. Measurement of bone turnover markers such as PTH may aid in the early diagnosis of the consequences of hypercortisolism on the bone.
{"title":"The Severity of Bone Loss: A Comparison Between Cushing’s Disease and Cushing’s Syndrome","authors":"R. Naguib, Eman Z. Elkemary, K. Elsharkawi","doi":"10.14740/jem857","DOIUrl":"https://doi.org/10.14740/jem857","url":null,"abstract":"Background: This study aimed to estimate the prevalence of osteoporosis among patients with adrenal Cushing’s syndrome (ACS) and Cushing’s disease (CD), to investigate whether there is a difference in the degree of osteoporosis between both groups; and if so, what factors may be responsible for this variation. Methods: This is a cross-sectional study in which data from 19 patients with CD and eight patients with ACS were analyzed. Osteo-porosis was assessed using the bone mineral density (BMD) of the lumbar spine using dual-energy X-ray absorptiometry (DEXA). Results: Bone loss was present in 81.5% of the patients with Cushing’s syndrome. Osteoporosis is nearly three times more common in ACS (62.5%) than in CD (26.3%). BMD at the lumbar spine was lower in patients with ACS than in patients with CD. ACS had significantly lower levels of dehydroepiandrosterone sulfate (DHEA-S) than CD. In comparison to the CD group, the serum parathyroid hormone (PTH) concentration in the ACS group was significantly higher. In the entire patient population, there was a statistically significant correlation between the DHEA-S and the lumbar BMD values. Conclusions: Patients with ACS have more severe osteoporosis than patients with CD, and the difference in DHEA-S concentrations might be important in explaining this difference. BMD examinations should be prioritized to enable rapid recognition and intervention for osteoporosis. Measurement of bone turnover markers such as PTH may aid in the early diagnosis of the consequences of hypercortisolism on the bone.","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44032455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Karimifar, Sina Abbaspour, A. Feizi, Mitra Heidarpour
{"title":"Predictors of Perioperative Hypertensive Crisis in Patients With Pheochromocytoma: A Retrospective Study","authors":"M. Karimifar, Sina Abbaspour, A. Feizi, Mitra Heidarpour","doi":"10.14740/jem853","DOIUrl":"https://doi.org/10.14740/jem853","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":"1 1","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42149250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sheehan’s Syndrome in a Fifty-Six-Year-Old Woman Presenting With a Retroperitoneal Mass: Perioperative Management During a Major Surgery","authors":"Rania Naguib","doi":"10.14740/jem858","DOIUrl":"https://doi.org/10.14740/jem858","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46409806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：